Supported by Longevity Biotech Report (report Sep 2026)

#1

https://longevity.technology/data/report/longevity-biotech-report-2026/

This is another report where they want your email address. Its more of a focus on finance and investment rather than science, however. You also need to read it on the web page.

claude-chat-opus-high-paid:

I recovered this copy by OCR, since it’s a printed web page with no text layer. The text came through well, but a few figure labels were garbled. I’ve relied only on figures stated clearly in the prose.

Longevity Biotech Report 2026 (Longevity.Technology / DLT)

What it is

This is an industry market-intelligence report, not a peer-reviewed paper. It was produced by Longevity.Technology’s Market Intelligence Unit (Phil Newman, Christine Belleza, Arwin Atis), sponsored by MuseCell Innovations, and built largely on their proprietary AI-assisted database, DLT. It covers 781 small- and mid-cap companies and 3,036 drug assets. It runs to 205 printed pages across 27 parts and closes with a sales pitch for DLT.

Summary

The central argument is that longevity biotech “has stopped being a thesis and started being a market.” It supports this with three separate revenue figures that it is careful not to add together.

  1. A top-down figure of $617BN a year by 2045. This is a TAM scenario that depends on assumptions:

    • regulators approve a gerotherapeutic category in 2035
    • treatment starts at age 45 worldwide
    • prices are GLP-1-like, around $6,000 per patient per year, with regional price erosion
    • 35% of eligible people take it up
    • the market takes 10 years to reach its plateau
    • no cap on share of healthcare budgets

  2. A bottom-up figure of $230BN a year from the existing pipeline. Each of the 3,036 assets is valued by risk-adjusted NPV. Approval odds come from BIO/Informa/QLS phase-transition data (9,704 programs, 2011 to 2020), and peak sales are benchmarked against approved comparator drugs in the same indication. The model runs 10,000 Monte Carlo iterations and caps each indication at its market size.

    • The clinical-stage tier (1,145 programs) contributes $164BN a year.
    • The earlier-stage tier contributes $66BN a year.
    • Because assets peak at different times, the highest single calendar year is about $182BN, in 2041.
    • All of this revenue comes through conventional disease indications.

  3. An additional $173BN a year of “gerotherapeutic optionality,” peaking in 2052. This is layered on top of the $230BN, giving $403BN in total. Of 660 screened assets, an LLM assigned 200 to the “aging prize”: 96 purely systemic aging assets and 104 disease assets with an aging option. It then applies a 35% success rate for gaining an aging label.

The report also makes several supporting claims:

  • Return on investment. It sets US spending of $330BN a year against the Scott, Ellison and Sinclair (Nature Aging, 2021) estimate that 10 extra years of life expectancy are worth $366.8TN. From this it claims a return of about 100x, or about 22x on an annual basis.
  • GLP-1s as proof of concept. GLP-1s are presented as a “generation-one gerotherapeutic,” assessed against Barzilai’s four criteria. The report notes they have not shown healthspan extension, and that they cause lean-mass loss that could be a problem in populations with lower BMI.
  • Regulation. It predicts 2035 for a formal gerotherapeutic pathway, citing ARPA-H’s PROSPR program, the FDA’s biomarker qualification record, and a proposed Multi-Disease Therapeutic Breakthrough Designation in PDUFA VIII.
  • Investment. It reports $18.4BN invested in 2025 and $12.1BN so far in 2026, with fewer but larger deals. Big Pharma runs 62% of industry trials on eight aging-pathway mechanisms (3,269 trials on ClinicalTrials.gov). Chinese companies are gaining ground through faster trials and licensing deals.
  • Structural findings.
    • Assets spanning two or more “Longevity Levels” hold 69% of projected revenue.
    • Drugs pursuing four or more indications are worth about 6x more each than single-indication drugs.
    • Assets linked to two or more hallmarks of aging account for about 88% of revenue.
  • Measurement. It acknowledges there is no gold-standard biological age measure. It cites the Kuo et al. finding that the slope of an epigenetic clock over time predicts mortality better than a single reading, and recommends building repeated methylation measurements into trials.

What is novel

Genuinely new, or at least new in combination:

  • Asset-level valuation of the whole longevity-adjacent pipeline. Valuing 3,036 assets individually with probability-weighted rNPV and Monte Carlo simulation, with a finite-market cap and deduplication, is more rigorous than the usual “sum the disease markets” approach to sizing.
  • Two-tier accounting. Separating conventional-indication revenue from an option value on a future aging label is a useful way to think about the question. It maps onto a real strategic choice: use the GLP-1 route (label first, aging claim later) or run aging endpoints in parallel from the start.
  • Tagging assets by longevity level and hallmark. This lets the authors look at where value sits by mechanism breadth, which is not commonly published.
  • An LLM-based eligibility screen with a “desirability halo” variable. The halo is the idea that benefits patients can feel drive adherence and pricing power. Treating that as a modelled factor, graded by strength of evidence, is new.
  • A direct check of Big Pharma’s trial share on ClinicalTrials.gov. Matching sponsors against the Pharma 50 list is a transparent and reproducible cross-check.
  • An interactive TAM explorer. Publishing the assumptions as adjustable sliders is good practice for a scenario model.

Not novel. The report assembles, rather than originates, the following: the hallmarks of aging, GLP-1s as candidate gerotherapeutics, Barzilai’s criteria, the Scott et al. valuation, the slope finding for epigenetic clocks, and the absence of a regulatory pathway for aging.

Critique

Conflicts of interest and independence

  • The report is sponsored by MuseCell Innovations. The sponsor’s CEO writes the foreword, the report contains a sponsored section on Muse cells, and it repeatedly names MuseCell as “one of the clearest examples.” The statement that “editorial control rests with Longevity.Technology” does not remove the concern.
  • It is also marketing for DLT. It includes chatbot prompts “for licensed users,” withholds the internal data behind the key $173BN screen, and ends with an invitation to book a call.
  • The reviewers are named and quoted with endorsements, but there is no independent peer review of the methods.
  • The practical effect is that the upbeat framing (“one of the highest-conviction public investment cases in modern economics”) should be discounted accordingly.

The 100x ROI calculation is not valid as stated

  • Scott et al.'s $366.8TN is a present value summed across the current population and future cohorts, for a hypothetical slowing of aging that adds 10 years of life expectancy. Comparing it with 10 years of drug spending mixes different time horizons.
  • More fundamentally, the calculation assumes the drugs deliver that 10-year gain. Nothing in the report, and nothing in the current evidence, shows any gerotherapeutic doing so. By the report’s own assessment, GLP-1s have not yet met the healthspan criterion.
  • So the ratio compares the value of an ideal outcome against the cost of a product whose effect size is unknown. At most it shows an upper bound on what society might be willing to pay. It does not show a return on investment.

The “conservative” label on the $617BN TAM is doubtful

  • Several of the defaults are aggressive:
    • 35% uptake across all over-45s worldwide, higher than the report’s own figure of about 20% at peak for GLP-1s
    • GLP-1-level pricing for preventive treatment of healthy people
    • the market-ceiling slider switched off, on the assumption that governments will find new budgets
  • Pricing and uptake usually move in opposite directions. Mass preventive use tends to arrive only at statin-like prices, as generics or under payer pressure.
  • It is a transparent scenario, which is to its credit. Calling it a “grounded baseline, not the bull case” is not justified.

The 2035 approval date is asserted rather than derived

  • The “three independent clocks” converging on 2035 are not independent. They are advocacy activity, an agency research program, and a legislative cycle.
  • The TAME trial has been unfunded or delayed for years. The report itself concedes there is no validated surrogate endpoint for aging, that CMS cannot build coverage without one, and that aging clocks correlate poorly with each other.
  • A single point estimate with no probability distribution is weak, because the timing of approval drives every downstream revenue figure.

Problems with the $173BN optionality model

  • A borrowed success rate. The 35% gerotherapeutic success rate is described as the published rate at which approved drugs gain any new indication. That is a different event from winning approval for an entirely new regulatory category with endpoints that do not yet exist.
  • A 100% capture assumption. The model sets the probability that tracked companies win the market, rather than Big Pharma, at 100%. Yet the report’s own data shows Big Pharma runs 62% of mechanism-relevant trials.
  • An LLM classification that cannot be checked. Eligibility was decided in a single structured LLM pass. The authors say it follows a rubric and is logged, but they give no accuracy check against human experts and no inter-rater agreement figures.
  • Contradictory framing. The report calls the screen “deliberately conservative” while noting that only 47 of the 200 prize-eligible assets have clinical-stage credibility.

The $230BN figure is mostly ordinary biotech

  • The cohort includes Biogen, Alnylam, Arrowhead and Innovent. Neurology, immunology and ophthalmology make up a large share of the total.
  • In effect, the report values a large slice of the SMID-cap disease pipeline and labels it longevity because the targets are age-related diseases.
  • The investment totals are likely inflated in the same way, and by counting headline business-development deal values, which include contingent milestone payments, as money invested.
  • The same boundary problem affects “longevity” versus “age-related disease” throughout.

The hallmark and multi-indication analyses do not test the geroscience thesis

  • The report says its data “can test directly” the geroscience prediction that aging-targeted drugs will be pursued across more indications. What it actually shows is that multi-indication and multi-hallmark assets carry more modelled revenue.
  • That result is largely built in:
    • revenue is summed per indication, so more indications mechanically means more revenue
    • hallmark links are assigned by the authors’ own classification
    • broad-mechanism drugs tend to sit in large metabolic and inflammatory markets
    • companies choose how many indications to pursue for commercial reasons
  • This is a correlation in portfolio data, not a biological test.

Other methodological and reporting gaps

  • The approval-odds benchmarks cover 2011 to 2020 and are not specific to aging. Aging trials may have lower success rates, given endpoint uncertainty and long durations.
  • There is no sensitivity analysis in the report itself. It is deferred to an online methodology page, and there are no confidence intervals on the headline figures despite the 10,000-run Monte Carlo.
  • The report mixes cash, headline deal values and PitchBook “funded to date” figures. The 4x jump in 2025 may reflect a handful of mega-rounds and BD deals rather than broad growth; the report half-acknowledges this with its “fewer, bigger checks” point.
  • It gives little attention to safety risks of treating healthy 45-year-olds for decades, even though it notes GLP-1 lean-mass loss. The same point applies to its assumption about long-term adherence to chronic preventive treatment.

Strengths worth acknowledging

  • The assumptions are transparent and adjustable.
  • It keeps disease-pathway revenue and aging-label revenue explicitly separate rather than double-counting them.
  • Its comparator-anchored peak sales, with a finite-market cap, are better than sizing by disease prevalence.
  • It is candid about the biomarker gap and about GLP-1s falling short on healthspan.
  • The trial-design recommendation, to build in repeated epigenetic-clock measurements, is practical and well supported.

Bottom line

The report is a useful, data-rich map of the longevity-adjacent pipeline, and its $230BN risk-adjusted valuation of conventional disease revenue is its most defensible output. The $617BN and $173BN figures are scenarios that depend on a regulatory pathway and an efficacy that have not been shown, and the 100x ROI claim rests on a flawed comparison. Given the sponsorship and the sales-funnel framing, the report is best read as a well-built bull case with transparent assumptions, not as a neutral forecast.